About a third of men with metastatic hormone-sensitive prostate cancer never reach undetectable PSA on standard doublet therapy, and half progress to castration-resistant disease within 20 months. That compression of the window for durable disease control is precisely what the FDA’s July 31 approval of Pluvicto in mHSPC is designed to address, extending lutetium Lu 177 vipivotide tetraxetan into an earlier and substantially larger patient population.
The approval rests on the Phase III PSMAddition trial, where Pluvicto added to ARPI plus androgen deprivation therapy reduced the risk of progression or death by 28% at primary analysis (HR 0.72; 95% CI: 0.58–0.90). An updated analysis pushed that figure to a 33% reduction (HR 0.67; 95% CI: 0.55–0.82), with an overall survival trend favoring the Pluvicto arm (HR 0.80; 95% CI: 0.63–1.01), though the OS data have not matured to a final read. That OS confidence interval crossing 1.0 is the live question in this dataset, and the final analysis will be the decisive trial moment for oncologists weighing treatment intensification against a therapy that carries a grade 3 or higher adverse event rate of 50.7% versus 43.0% for standard of care alone. Dry mouth, fatigue, and nausea dominated the all-grade toxicity profile, consistent with findings from VISION and PSMAfore.
The strategic scope of this approval is real. PSMA expression is present in more than 80% of prostate cancer patients, and Novartis estimates the mHSPC indication nearly doubles the eligible patient population, building on the March 2025 pre-chemotherapy mCRPC expansion. The mHSPC landscape already includes oral ARPIs, and darolutamide received its own mCSPC approval in June 2025 without requiring chemotherapy, so Pluvicto enters a field with established competition. What differentiates the radioligand approach is mechanism, not exclusivity. Pluvicto is now the only PSMA-targeted agent approved across the full metastatic spectrum, and Novartis has five U.S. manufacturing sites operational or under construction, with a stated delivery window of five days to treatment centers.
The single marker worth tracking from here is the final overall survival readout from PSMAddition. Regulatory approval without a mature OS benefit in a hormone-sensitive setting will face scrutiny from payers and guideline committees alike, and that result will determine whether Pluvicto becomes a standard triplet component or remains a precision option for select patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
